Skip to content

Verge Genomics

Verge Genomics is a San Francisco-based company that started in 2015 with a bet on human data and became Verge Labs in 2026, a frontier AI lab building world models of human disease biology for neuroscience drug discovery.

Last updated September 16, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Verge Genomics started in 2015 with a bet on human data, building a discovery engine that learned directly from multi-modal human data rather than using mice to predict what works in humans. Over ten years it built one of the world's largest curated patient datasets from CNS tissue and produced an AI-discovered drug that reached the clinic and was tested in ALS patients. In 2026 the company became Verge Labs, a frontier AI lab focused on building world models of human disease biology to predict not only which targets to drug, but also which patients to drug them in. Its platform is built on one of the largest proprietary collections of multimodal patient brain data, including deep molecular profiling on 12,000+ brains across 6,000 patients and a physical inventory of 900+ frozen brain tissue samples.

History

Verge Labs started as Verge Genomics in 2015 with a bet on human data. While most of the field used mice to predict what works in humans, the company built a discovery engine that learned directly from multi-modal human data. Over ten years, it built the world's largest curated patient datasets from CNS tissue and produced an AI-discovered drug that reached the clinic and was tested in ALS patients. That clinical trial taught the company that its first-generation platform could identify new biology and targets, but missed which patients to drug those targets in. In 2026, the company became Verge Labs, a frontier AI lab focused on building world models of human disease biology to predict not only which targets to drug, but also which patients to drug them in.

Products and positioning

Frontier AI for human biology, starting with the brain; all-in-human foundation models to transform neuroscience drug development.

  • vBx foundation models

    All-in-human foundation models to transform neuroscience drug development; vBx-1.0 enriches a Parkinson's trial for L-DOPA responders, lifting the responder fraction from 52% to 69% and shrinking required enrollment by 43% at fixed power.

Sources2 sources

Cite this profile: Cite the canonical profile. /brand-wiki/verge-genomics-united-states · Editorial policy · How profiles are compiled